...and diabetes patients
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific claims superior two-year results for Taxus compared to Cypher and bare-metal stents in a population of patients with diabetes, based on 708-patient registry data reported at the AHA Scientific Sessions Nov. 14. In the European T-Search/Research study, the target vessel revascularization rate was 9.7% for Taxus compared with 15.3% for Cypher and 19.5% for bare-metal stents. MACE (major adverse cardiac event) rates were 21.2% with Taxus, 28.9% with Cypher and 29.7% with bare-metal stents. Data from 1,182 diabetic patients in another Boston Scientific-sponsored registry reported earlier this year showed no statistically significant difference between the two drug-eluting products (1"The Gray Sheet" March 20, 2006, p. 4). Diabetics make up 25% of patients receiving coronary interventional procedures in the U.S., Boston Scientific says...